Advertisement

Pathologie pp 47-87 | Cite as

Neoplastische Bildungsstörungen der Hämatopoiese mit erhaltener Ausreifung

  • Hans H. KreipeEmail author
Chapter

Zusammenfassung

In diesem Kapitel werden nach den neuen Klassifikationskriterien der WHO die myeloproliferativen Neoplasien (MPN), die myelodysplasisch-myeloproliferativen Neoplasien (MDS/MPN) und die myelodysplastischen Syndrome (MDS) behandelt. Systematische Darstellung der Entitäten, ihrer Differenzialdiagnose und Prognose bilden die Basis für die relevante Knochenmarkdiagnostik. Bei den MPN (chronische myeloische Leukämie, Polycythämia vera, essentielle Thrombocythämie, primäre Myelofibrose, chronische Neutrophilenleukämie, die chronische Eosinophilenleukämie) beruht die Diagnose auf dem zytologischen und histologischen Nachweis einer Myeloproliferation in Verbindung mit der Identifikation charakteristischer klonaler genetischer Alterationen; bei den MDS/MPN (chronische myelo-monozytäre Leukämien, atypische chronische myloische Leukämie, refraktäre Anämie mit Ringsideroblasten und Thrombozytose) auf dem Nachweis gleichzeitig vermehrt und vermindert gebildeter Zellreihen; bei der heterogenen Gruppe der MDS als klonale Stammzellerkrankungen auf der die molekulargenetischen Definition der Blasten und deren Gehalt in Blut und Knochenmark.

Literatur

  1. 1.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefGoogle Scholar
  2. 2.
    Bain BJ, Brunning RD, Vardiman JW, Thiele J (2008) Chronic neutrophilic leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 38–39Google Scholar
  3. 3.
    Bain BJ, Gilliland DG, Horny HP, Vardiman JW (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 68–73Google Scholar
  4. 4.
    Bain BJ, Gilliland DG, Vardiman JW, Horny HP (2008) Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 51–53Google Scholar
  5. 5.
    Bartels S, Lehmann U, Büsche G, Schlue J, Kreipe H (2016) Evolution of chronic myelomonocytic leukemia to myeloproliferative neoplasm. Ann Hematol 95:1377–1380CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H (2015) SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia 29:253–255CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bartels S, Schipper E, Hasemeier B, Kreipe H, Lehmann U (2016) Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget 7:30084–30093PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Baumann I, Bennett JM, Niemeyer CM, Thiele J, Shannon K (2008) Juvenile myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 82–84Google Scholar
  9. 9.
    Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA et al (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99:381–383CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C, Cox C (1994) The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French–American–British co-operative leukaemia group. Br J Haematol 87:746–754CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Boiocchi L, Espinal-Witter R, Geyer JT, Steinhilber J, Bonzheim I, Knowles DM, Fend F, Orazi A (2013) Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Mod Pathol 26:204–212CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS (2010) Advances in the 5q-syndrome. Blood 116:5803–5811CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Brunning RD, Bennett JM, Matutes E, Orazi A, Vardiman JW, Thiele J (2008) Refractory cytopenia with multilineage dysplasia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 98–99Google Scholar
  15. 15.
    Brunning RD, Hasserjian RP, Porwit A, Bennett JM, Orazi A, Thiele J, Hellstrom-Lindberg EK (2008) Refractory cytopenia with unilineage dysplasia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 94–85Google Scholar
  16. 16.
    Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Bauman I, Vardiman JW, Hellstrom-Lindberg EK (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 68–93Google Scholar
  17. 17.
    Buhr T, Busche G, Choritz H, Langer F, Kreipe H (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 119:152–158CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H (2012) European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 97:360–365PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Burkhardt R, Bartl R, Jäger K, Frisch B, Kettner G, Mahl G, Sund M (1986) Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol 39:237–252PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Büsche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H et al (2007) Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 21:2420–2427CrossRefGoogle Scholar
  21. 21.
    Büsche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Göhring G, Schlegelberger B, Bock O, Georgii A, Kreipe H (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313–322CrossRefGoogle Scholar
  22. 22.
    Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al (2012) Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 44:1179–1181PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 27:2991–2999PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Carbuccia N, Murati A, Trouplin V et al (2009) Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23:2183–2186CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cazzola M, Porta DMG, Malcovati L (2013) The genetic basis of myelodysplasia and its clinical relevance. Blood 122:4021–4034PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Cazzola M, Kralovics R (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123:3714–3719CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201–1214CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6:372–375PubMedPubMedCentralGoogle Scholar
  30. 30.
    Delhommeau F, Dupont S, Valle DV, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360:2289–2301CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ernst T, Chase AJ, Score J et al (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722–726PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Foucar K, Viswanatha DS, Wilson CS (2008) Non-neoplastic disorders of bone marrow. ARP Press, WashingtonGoogle Scholar
  33. 33.
    Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392–397PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Genovese G, Kähler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477–2487PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Georgii A, Buhr T, Buesche G, Kreft A, Choritz H (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22(Suppl 1):15–29CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P et al (2012) Survival,prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 26:1286–1292CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C et al (2012) Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res 36:727–734CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Germing U, Gattermann N, Minning H, Heyll A, Aul C (1998) Problems in the classification of CMML – dysplastic versus proliferative type. Leuk Res 22:871–878CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS et al (2013) The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 25:1193–1202CrossRefGoogle Scholar
  40. 40.
    Gomori G (1937) Silver impregnation of reticulum in paraffin sections. Am J Pathol 13:993–1002, 1005PubMedCentralPubMedGoogle Scholar
  41. 41.
    Green A, Beer P (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:369–370CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Guglielmelli P, Biamonte F, Score J et al (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood 118:5227–5234CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NC, Vannucchi AM, Tefferi A (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28:1804–1810CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C (2007) Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 86:311–327CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al (2014) Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28:241–247CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Hasserjian RP, Gattermann BJM, Brunning RD, Thiele J (2008) Refractory anaemia with ring sideroblasts. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 96–97Google Scholar
  49. 49.
    Hasserjian RP, Le Beau MM, List AF, Bennett JM, Thiele J (2008) Myelodysplastic syndrome with isolated del(5q). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 102–103Google Scholar
  50. 50.
    Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M (2016) Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 127:392–399PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G et al (2007) Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 109:4106–4107CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H (2009) JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 37:1186–1193CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Jaiswal S, Fontanillas P, Flannick J et al (2014) Age related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Jan M, Snyder TM, Corces-Zimmerman MR et al (2012) Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 4:149ra118PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Koppikar P, Bhagwat N, Kilpivaara O et al (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489:155–159PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukaemia 24:1094–1096CrossRefGoogle Scholar
  59. 59.
    Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108:1377–1378CrossRefGoogle Scholar
  61. 61.
    Kreipe H, Hussein K, Göhring G, Schlegelberger B (2011) Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia. J Hematop 4:61–68CrossRefGoogle Scholar
  62. 62.
    Kreipe H, Jaquet K, Felgner J, Radzun HJ, Parwaresch MR (1991) Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78:1814–1817Google Scholar
  63. 63.
    Kröger N, Deeg JH, Olavarria E et al (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 29:2126–2133CrossRefGoogle Scholar
  64. 64.
    Kröger N, Thiele J, Zander A et al (2007) Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 35:1719–1722CrossRefGoogle Scholar
  65. 65.
    Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H et al (2016) Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis – a consensus-based study. Histopathology 68:905–915CrossRefGoogle Scholar
  66. 66.
    Kvasnicka HM, Thiele J (2006) The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 32:362–371CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K et al (2015) MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 126:2355–2361PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Lehmann U, Bartels S, Hasemeier B, Geffers R, Schlue J, Büsche G, Hussein K, Kreipe H (2013) SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis. Blood 121:4011–4012CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Löffler H, Rastetter J, Haferlach T (2004) Atlas der klinischen Hämatologie. Springer, BerlinCrossRefGoogle Scholar
  70. 70.
    Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220–2228CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M, Okuno Y, Hirsch C, Kuzmanovic T, Sato Y, Sato-Otsubo A, LaFramboise T, Hosono N, Shiraishi Y, Chiba K, Haferlach C, Kern W, Tanaka H, Shiozawa Y, Gómez-Seguí I, Husseinzadeh HD, Thota S, Guinta KM, Dienes B, Nakamaki T, Miyawaki S, Saunthararajah Y, Chiba S, Miyano S, Shih LY, Haferlach T, Ogawa S, Maciejewski JP (2017) Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet 49:204–212CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Martincorena I, Campbell PJ (2015) Somatic mutation in cancer and normal cells. Science 349:1483–1489CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Drucker BJ, Gotlib J, O’Hare T, Deininger MW (2015) Age-related mutations and chronic myeloid leukemia. Leukemia 30:906–913PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781–1790PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al (2012) SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120:3080–3088PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, Cazzola M, Fenaux P, Germing U, Hellström-Lindberg E, Jinnai I, Manabe A, Matsuda A, Niemeyer CM, Sanz G, Tomonaga M, Vallespi T, Yoshimi A, International Working Group on Morphology of Myelodysplastic Syndrome (2008) Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L et al (2015) An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica 100:1117–1130PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.
    Muramatsu H, Makishima H, Maciejewski JP (2012) Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. Semin Oncol 39:67–73PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405PubMedCentralPubMedCrossRefGoogle Scholar
  80. 80.
    Nangalia J, Nice FL, Wedge DC et al (2015) DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica 100:e438–e442PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Nowell PC, Hungerford DA (1961) Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 27:1013–1035PubMedPubMedCentralGoogle Scholar
  82. 82.
    Orazi A, Bennett JM, Brunning RD, Bain BJ, Thiele J (2008) Chronic myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 76–79Google Scholar
  83. 83.
    Orazi A, Brunning RD, Hasserjian RP, Germing U, Thiele J (2008) Refractory anaemia excess blasts. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 100–101Google Scholar
  84. 84.
    Orazi A, O’Malley DP, Jiang J, Vance GH, Thomas J, Czader M, Fang W, An C, Banks PM (2005) Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol 18:603–614CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitripolou D, Guiglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Camphell PJ, Green AR (2015) Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 372:601–612PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122:3616–3627PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, Ketterling RP, Maxson JE, Tyner JW, Tefferi A (2013) CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27:1870–1873PubMedCentralPubMedCrossRefGoogle Scholar
  88. 88.
    Patnaik MM, Parikh SA, Hanson CA, Tefferi A (2014) Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 165:273–286CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, Antolini L, Mologni L, Donadoni C, Papaemmanuil E, Schnittger S, Kim DW, Boultwood J, Rossi F, Gaipa G, De Martini GP, di Celle PF, Jang HG, Fantin V, Bignell GR, Magistroni V, Haferlach T, Pogliani EM, Campbell PJ, Chase AJ, Tapper WJ, Cross NC, Gambacorti-Passerini C (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18–24CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Porwit A, McCullough J, Erber WN (Hrsg) (2011) Blood and bone marrow pathology. Churchill Livingstone, New YorkGoogle Scholar
  91. 91.
    Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357:258–265CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16PubMedCentralPubMedCrossRefGoogle Scholar
  93. 93.
    Stegelmann F, Bullinger L, Schlenk RF et al (2011) DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25:1217–1219CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610–618PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Taskesen E, Havermans M, van Lom K et al (2014) Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and NA methylation profiling. Blood 123:3327–3335CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Tefferi A (2016) Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol 91:50–58CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Tefferi A, Finke CM, Lasho TL et al (2014) U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 28:431–433CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Tefferi A, Guglielmelli P, Lasho TL et al (2014) CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 28:1494–1500CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Tefferi A, Jimma T, Sulai NH et al (2012) IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26:475–480CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Birgegard G (2008) Polycythaemia vera. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 40–43Google Scholar
  101. 101.
    Thiele J, Kvasnicka HM, Orazi A, Tefferi A, Gisslinger H (2008) Essential thrombocythaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 48–50Google Scholar
  102. 102.
    Thiele J, Kvasnicka HM, Tefferi A, Barosi G, Orazi A, Vardiman JW (2008) Primary myelofibrosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 44–47Google Scholar
  103. 103.
    Thiele J, Kvasnicka HM, Facchetti F et al (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128–1132Google Scholar
  104. 104.
    Thol F, Kade S, Schlarmann C, Löffeld P, Morgan M, Krauter J et al (2012) Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119:3578–3584CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1874) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437–438CrossRefGoogle Scholar
  106. 106.
    Vannucchi AGP, Rotunno G et al (2014) Mutation-enhanced international prognostic scoring system (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. Blood 124:405CrossRefGoogle Scholar
  107. 107.
    Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861–1869CrossRefGoogle Scholar
  108. 108.
    Vardiman JW, Bennett JM, Bain BJ, Baumann I, Thiele J, Orazi A (2008) Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 85–86Google Scholar
  109. 109.
    Vardiman JW, Bennett JM, Bain BJ, Brunning RD, Thiele J (2008) Atypical chronic myelogenous leukemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 80–81Google Scholar
  110. 110.
    Vardiman JW, Melo JV, Baccarani M, Thiele J (2008) Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 32–37Google Scholar
  111. 111.
    Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:2645–2651PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, Paul B, Harrison CN, Green AR, Campbell PJ (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111:60–70CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472–1478PubMedCentralPubMedCrossRefGoogle Scholar
  114. 114.
    Yoshida K, Sanada M, Shiraishi Y et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Institut für PathologieMedizinische Hochschule Hannover (MHH)HannoverDeutschland

Personalised recommendations